LIVIVO - Search results -

Search results

Result 1 - 10 of total 38

Search options

Article: Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS Study.

Heyrman, Bert / Meers, Stef / De Becker, Ann / Wouters, Kristien / Van Hoof, Achiel / Van De Velde, Ann / Graux, Carlos / Mazure, Dominiek / Selleslag, Dominik / Maes, Helena / Lemmens, Jan / Beckers, Marielle / Breems, Dimitri / Sid, Sélim / Berneman, Zwi / Anguille, Sébastien

Cancers

2023 Volume 15, Issue 13

Abstract: Patients with myelodysplastic syndromes suffer from an impaired quality of life that is only partially explained by physical symptoms. In an observational study, we aimed to investigate the impact of current MDS treatments and the influence of disease ... ...

Abstract	Patients with myelodysplastic syndromes suffer from an impaired quality of life that is only partially explained by physical symptoms. In an observational study, we aimed to investigate the impact of current MDS treatments and the influence of disease perception on quality of life. Serial measurement of health-related quality of life was performed by 'the QUALMS', a validated MDS-specific patient reported outcome tool. Disease perception was evaluated by means of the Brief Illness Perception Questionnaire (B-IPQ). We prospectively collected data on 75 patients that started on a new treatment and could not demonstrate a significant change in QUALMS score or B-IPQ score during treatment. Six out of eight items evaluated in the B-IPQ correlated significantly with QUALMS score. In this small sample, no significant difference in QUALMS score was found between lower vs. higher risk MDS patients or other studied variables, e.g., targeted hemoglobin showed no correlation with QUALMS score. In daily practice attention must be paid to initial formation of disease perception as it correlates independently with health-related quality of life and does not change during treatment (clinicaltrials.gov identifier: NCT04053933).
Language	English
Publishing date	2023-06-22
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers15133296
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum.

Breems, Dimitri A / Löwenberg, Bob

Haematologica

2011 Volume 96, Issue 4, Page(s) 491–493

MeSH term(s)	Humans ; Karyotyping ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/therapy ; Monosomy/genetics ; Prognosis
Language	English
Publishing date	2011-03-31
Publishing country	Italy
Document type	Comment ; Editorial
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2011.043208
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.

Tettero, Jesse M / Ngai, Lok Lam / Bachas, Costa / Breems, Dimitri A / Fischer, Thomas / Gjertsen, Bjorn T / Gradowska, Patrycja / Griskevicius, Laimonas / Janssen, Jeroen J W M / Juliusson, Gunnar / Maertens, Johan / Manz, Markus G / Pabst, Thomas / Passweg, Jakob / Porkka, Kimmo / Valk, Peter J M / Löwenberg, Bob / Ossenkoppele, Gert J / Cloos, Jacqueline

Haematologica

2023 Volume 108, Issue 10, Page(s) 2794–2798

MeSH term(s)	Humans ; Transplantation, Homologous ; Hematopoietic Stem Cell Transplantation ; Leukemia, Myeloid, Acute/therapy ; Neoplasm, Residual ; Recurrence ; Transplantation Conditioning
Language	English
Publishing date	2023-10-01
Publishing country	Italy
Document type	Letter
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2022.282639
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.

Sekeres, Mikkael A / Schuster, Michael / Joris, Magalie / Krauter, Jürgen / Maertens, Johan / Breems, Dimitri / Gyan, Emmanuel / Kovacsovics, Tibor / Verma, Amit / Vyas, Paresh / Wang, Eunice S / Ching, Keith / O'Brien, Thomas / Gallo Stampino, Corrado / Ma, Weidong Wendy / Kudla, Arthur / Chan, Geoffrey / Zeidan, Amer M

Annals of hematology

2022 Volume 101, Issue 8, Page(s) 1689–1701

Abstract: This phase 1b study evaluated glasdegib (100 mg once daily) + azacitidine in adults with newly diagnosed acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) who were ineligible for ... ...

Abstract	This phase 1b study evaluated glasdegib (100 mg once daily) + azacitidine in adults with newly diagnosed acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) who were ineligible for intensive chemotherapy. Of 72 patients enrolled, 12 were in a lead-in safety cohort (LIC) and 60 were in the AML and MDS (including CMML) expansion cohorts. In the LIC, the safety profile of glasdegib + azacitidine was determined to be consistent with those of glasdegib or azacitidine alone, with no evidence of drug-drug interaction. In the expansion cohort, the most frequently (≥ 10%) reported non-hematologic Grade ≥ 3 treatment-emergent adverse events were decreased appetite, electrocardiogram QT prolongation, and hypertension in the AML cohort and sepsis, diarrhea, hypotension, pneumonia, and hyperglycemia in the MDS cohort. Overall response rates in the AML and MDS cohorts were 30.0% and 33.3%, respectively; 47.4% and 46.7% of patients who were transfusion dependent at baseline achieved independence. Median overall survival (95% confidence interval) was 9.2 (6.2-14.0) months and 15.8 (9.3-21.9) months, respectively, and response was associated with molecular mutation clearance. Glasdegib + azacitidine in patients with newly diagnosed AML or MDS demonstrated an acceptable safety profile and preliminary evidence of clinical benefits.Trial registration: ClinicalTrials.gov NCT02367456.
MeSH term(s)	Adult ; Azacitidine/adverse effects ; Benzimidazoles/adverse effects ; Drug Therapy, Combination/adverse effects ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Myelodysplastic Syndromes/drug therapy ; Phenylurea Compounds/adverse effects ; Risk Assessment ; Treatment Outcome
Chemical Substances	Benzimidazoles ; Phenylurea Compounds ; glasdegib (K673DMO5H9) ; Azacitidine (M801H13NRU)
Language	English
Publishing date	2022-04-30
Publishing country	Germany
Document type	Clinical Trial, Phase I ; Journal Article
ZDB-ID	1064950-5
ISSN	1432-0584 ; 0939-5555 ; 0945-8077
ISSN (online)	1432-0584
ISSN	0939-5555 ; 0945-8077
DOI	10.1007/s00277-022-04853-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.

Ngai, Lok Lam / Hanekamp, Diana / Janssen, Fleur / Carbaat-Ham, Jannemieke / Hofland, Maaike A M A / Fayed, Mona M H E / Kelder, Angèle / Oudshoorn-van Marsbergen, Laura / Scholten, Willemijn J / Snel, Alexander N / Bachas, Costa / Tettero, Jesse M / Breems, Dimitri A / Fischer, Thomas / Gjertsen, Bjørn T / Griškevičius, Laimonas / Juliusson, Gunnar / van de Loosdrecht, Arjan A / Maertens, Johan A /

Manz, Markus G / Pabst, Thomas / Passweg, Jakob R / Porkka, Kimmo / Valk, Peter J M / Gradowska, Patrycja / Löwenberg, Bob / de Leeuw, David C / Janssen, Jeroen J W M / Ossenkoppele, Gert J / Cloos, Jacqueline

Blood

2023 Volume 141, Issue 21, Page(s) 2657–2661

MeSH term(s)	Humans ; Prognosis ; Antigens, CD34 ; ADP-ribosyl Cyclase 1 ; Leukemia, Myeloid, Acute ; Stem Cells ; Neoplastic Stem Cells ; Flow Cytometry
Chemical Substances	Antigens, CD34 ; ADP-ribosyl Cyclase 1 (EC 3.2.2.6)
Language	English
Publishing date	2023-03-09
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.2022019160
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes.

Garcia-Manero, Guillermo / Diez-Campelo, Maria / Vellenga, Edo / Jacoby, Meagan A / Merchan, Brayan / Breems, Dimitri / Cortelezzi, Agostino / Doronin, Vadim / Gomez, Valle / Beckers, Marielle / Della Porta, Matteo Giovanni / Varsos, Helen / Xiu, Liang / DeAngelis, Nikki / Nnane, Ivo / Rose, Esther / van Eygen, Koen

American journal of hematology

2021 Volume 96, Issue 4, Page(s) E111–E114

MeSH term(s)	ADP-ribosyl Cyclase 1/antagonists & inhibitors ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal/therapeutic use ; Erythrocyte Transfusion ; Female ; Fever/chemically induced ; Follow-Up Studies ; Humans ; Immunologic Factors/adverse effects ; Immunologic Factors/therapeutic use ; Male ; Membrane Glycoproteins/antagonists & inhibitors ; Middle Aged ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/epidemiology ; Myelodysplastic Syndromes/therapy ; Neutropenia/chemically induced ; Pneumonia/chemically induced ; Proof of Concept Study ; Risk ; Thrombocytopenia/chemically induced
Chemical Substances	Antibodies, Monoclonal ; Immunologic Factors ; Membrane Glycoproteins ; daratumumab (4Z63YK6E0E) ; CD38 protein, human (EC 3.2.2.5) ; ADP-ribosyl Cyclase 1 (EC 3.2.2.6)
Language	English
Publishing date	2021-01-31
Publishing country	United States
Document type	Clinical Trial, Phase II ; Comparative Study ; Letter ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	196767-8
ISSN	1096-8652 ; 0361-8609
ISSN (online)	1096-8652
ISSN	0361-8609
DOI	10.1002/ajh.26095
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1251: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed.

Bakunina, Katerina / Putter, Hein / Versluis, Jurjen / Koster, Eva A S / van der Holt, Bronno / Manz, Markus G / Breems, Dimitri A / Gjertsen, Bjorn T / Cloos, Jacqueline / Valk, Peter J M / Passweg, Jakob / Pabst, Thomas / Ossenkoppele, Gert J / Löwenberg, Bob / Cornelissen, Jan J / de Wreede, Liesbeth C

Cancer medicine

2021 Volume 11, Issue 3, Page(s) 630–640

Abstract: Clofarabine is an active antileukemic drug for subgroups of patients with acute myeloid leukemia (AML). Multi-state models can provide additional insights to supplement the original intention-to-treat analysis of randomized controlled trials (RCT). We re- ...

Abstract	Clofarabine is an active antileukemic drug for subgroups of patients with acute myeloid leukemia (AML). Multi-state models can provide additional insights to supplement the original intention-to-treat analysis of randomized controlled trials (RCT). We re-analyzed the HOVON102/SAKK30/09 phase III RCT for newly diagnosed AML patients, which randomized between standard induction chemotherapy with or without clofarabine. Using multi-state models, we evaluated the effects of induction chemotherapy outcomes (complete remission [CR], measurable residual disease [MRD]), and post-remission therapy with allogeneic stem cell transplantation [alloSCT] on relapse and death. Through the latter a consistent reduction in the hazard of relapse in the clofarabine arm compared to the standard arm was found, which occurred irrespective of MRD status or post-remission treatment with alloSCT, demonstrating a strong and persistent antileukemic effect of clofarabine. During the time period between achieving CR and possible post-remission treatment with alloSCT, non-relapse mortality was higher in patients receiving clofarabine. An overall net benefit of treatment with clofarabine was identified using the composite endpoint current leukemia-free survival (CLFS). In conclusion, these results enforce and extend the earlier reported beneficial effect of clofarabine in AML and show that multi-state models further detail the effect of treatment on competing and series of events.
MeSH term(s)	Clofarabine/therapeutic use ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Recurrence ; Remission Induction ; Treatment Outcome
Chemical Substances	Clofarabine (762RDY0Y2H)
Language	English
Publishing date	2021-12-24
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	2659751-2
ISSN	2045-7634 ; 2045-7634
ISSN (online)	2045-7634
ISSN	2045-7634
DOI	10.1002/cam4.4392
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.

Blood

2022 Volume 139, Issue 15, Page(s) 2347–2354

Abstract: Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact assessment of prognostic impact for individual patients. We performed in-depth clinical and molecular ...

Abstract	Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact assessment of prognostic impact for individual patients. We performed in-depth clinical and molecular analysis of mutant TP53 AML and MDS-EB to dissect the molecular characteristics in detail and determine its impact on survival. We performed next-generation sequencing on 2200 AML/MDS-EB specimens and assessed the TP53 mutant allelic status (mono- or bi-allelic), the number of TP53 mutations, mutant TP53 clone size, concurrent mutations, cytogenetics, and mutant TP53 molecular minimal residual disease and studied the associations of these characteristics with overall survival. TP53 mutations were detected in 230 (10.5%) patients with AML/MDS-EB with a median variant allele frequency of 47%. Bi-allelic mutant TP53 status was observed in 174 (76%) patients. Multiple TP53 mutations were found in 49 (21%) patients. Concurrent mutations were detected in 113 (49%) patients. No significant difference in any of the aforementioned molecular characteristics of mutant TP53 was detected between AML and MDS-EB. Patients with mutant TP53 have a poor outcome (2-year overall survival, 12.8%); however, no survival difference between AML and MDS-EB was observed. Importantly, none of the molecular characteristics were significantly associated with survival in mutant TP53 AML/MDS-EB. In most patients, TP53 mutations remained detectable in complete remission by deep sequencing (73%). Detection of residual mutant TP53 was not associated with survival. Mutant TP53 AML and MDS-EB do not differ with respect to molecular characteristics and survival. Therefore, mutant TP53 AML/MDS-EB should be considered a distinct molecular disease entity.
MeSH term(s)	Cytogenetics ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Mutation ; Myelodysplastic Syndromes/diagnosis ; Tumor Suppressor Protein p53/genetics
Chemical Substances	TP53 protein, human ; Tumor Suppressor Protein p53
Language	English
Publishing date	2022-02-19
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.2021014472
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.

Frontiers in oncology

2022 Volume 12, Page(s) 999822

Abstract: Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has proven to be an important prognostic biomarker in acute myeloid leukemia (AML). In addition, MRD is increasingly used to guide consolidation treatment towards a non- ... ...

Abstract	Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has proven to be an important prognostic biomarker in acute myeloid leukemia (AML). In addition, MRD is increasingly used to guide consolidation treatment towards a non-allogenic stem cell transplantation treatment for MRD-negative patients in the ELN-2017 intermediate risk group. Currently, measurement of MFC-MRD in bone marrow is used for clinical decision making after 2 cycles of induction chemotherapy. However, measurement after 1 cycle has also been shown to have prognostic value, so the optimal time point remains a question of debate. We assessed the independent prognostic value of MRD results at either time point and concordance between these for 273 AML patients treated within and according to the HOVON-SAKK 92, 102, 103 and 132 trials. Cumulative incidence of relapse, event free survival and overall survival were significantly better for MRD-negative (<0.1%) patients compared to MRD-positive patients after cycle 1 and cycle 2 (
Language	English
Publishing date	2022-10-10
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2022.999822
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

Hilberink, Jacobien R / van Zeventer, Isabelle A / Chitu, Dana A / Pabst, Thomas / Klein, Saskia K / Stussi, Georg / Griskevicius, Laimonas / Valk, Peter J M / Cloos, Jacqueline / van de Loosdrecht, Arjan A / Breems, Dimitri / van Lammeren-Venema, Danielle / Boersma, Rinske / Jongen-Lavrencic, Mojca / Fehr, Martin / Hoogendoorn, Mels / Manz, Markus G / Söhne, Maaike / van Marwijk Kooy, Rien /

Deeren, Dries / van der Poel, Marjolein W M / Legdeur, Marie Cecile / Tick, Lidwine / Chalandon, Yves / Ammatuna, Emanuele / Blum, Sabine / Löwenberg, Bob / Ossenkoppele, Gert J / Huls, Gerwin

Blood cancer journal

2023 Volume 13, Issue 1, Page(s) 93

Abstract: Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical ... ...

Abstract	Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery < 9 and 17% ADL index < 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age > 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.
MeSH term(s)	Humans ; Male ; Female ; Aged ; Decitabine/therapeutic use ; Myelodysplastic Syndromes/genetics ; Leukemia, Myeloid, Acute/genetics ; Mutation ; Treatment Outcome
Chemical Substances	Decitabine (776B62CQ27)
Language	English
Publishing date	2023-06-19
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2600560-8
ISSN	2044-5385 ; 2044-5385
ISSN (online)	2044-5385
ISSN	2044-5385
DOI	10.1038/s41408-023-00850-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito